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 Abstract  
Epithelial Mesenchymal Transition (EMT) plays key roles during lung development and 
many lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), lung cancer 
and pulmonary fibrosis. Here, integrating morphological observations with underlying 
molecular mechanisms, we highlight the functional role of EMT in lung development and 
injury repair, and discuss how it can contribute to pathogenesis of chronic lung disease. We 
discuss the evidence of manifestation of EMT and its potential driving role in COPD, 
idiopathic pulmonary fibrosis (IPF), bronchiolitis obliterans syndrome (BOS), and lung 
cancer, while noting that all cells need not display a full EMT in any of these contexts, i.e. 
often cells co-express epithelial and mesenchymal markers but do not fully convert to 
extracellular matrix-producing fibroblasts. Finally, we discuss recent therapeutic attempts to 
restrict EMT in chronic lung disease. 
 
 
What is epithelial to mesenchymal transition (EMT)?  
EMT is a biological process in which epithelial cells lose their traits of cell-cell adhesion and 
apico-basal polarity, and gain some mesenchymal traits of migration, invasion, and producing 
extracellular matrix (ECM) components (Kalluri and Weinberg, 2009). These traits often lead 
to degradation of underlying basement membrane; thus, the fragmented anatomical changes 
in basement membrane has been observed to be associated with EMT and now considered as 
a key hallmark of the process (Kalluri and Weinberg, 2009). An often noted hallmark of 
EMT is the loss of epithelial cell-cell adhesion molecule CDH1 (E-cadherin), and/or a 
concomitant gain of mesenchymal markers such as CDH2 (N-cadherin), VIM (Vimentin), 
and/or αSMA (alpha-smooth muscle actin) (Nieto et al., 2016).  
 
EMT was initially described in 1982 as an ‘epithelial mesenchymal transformation’. But, 
with a better molecular and functional characterization, the term ‘transformation’ has been  
replaced with ‘transition’ to reflect its reversible nature as observed during embryogenesis 
(type I EMT), wound healing and fibrosis (type II EMT) and cancer metastasis (type III 
EMT) (Jolly et al., 2015). Recent investigations in all these contexts have underscored that 
EMT and its reverse process MET (Mesenchymal to Epithelial Transition) are not binary, i.e. 
‘all-or-none’ processes (Nieto et al., 2016). Instead, cells can display a spectrum of hybrid 
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states ranging from being fully epithelial to fully mesenchymal (Jolly et al., 2015), and a 
hybrid epithelial/ mesenchymal (E/M) state may be stable phenotype that cells can display, 
unless forced out from that state due to external factors (Figure 1). Such hybrid state(s) may 
enable amalgamated epithelial and mesenchymal traits such as adhesion and migration 
leading to collective cell migration. Cells leading this form of collective migration tend to 
display mesenchymal features transiently, while still exhibiting cell-cell contact with follower 
cells, as noted during wound healing, carcinoma dissemination, branching morphogenesis etc. 
(Revenu and Gilmour, 2009; Nieto et al., 2016). Given the pathological and physiological 
significance of hybrid E/M phenotype, its functional implications in all these contexts 
necessitate a detailed investigation.  
 
EMT is known to drive key steps in multiple stages of embryonic development, - 
gastrulation, neural crest migration, and heart development. Genetic studies have identified 
many signaling pathways that can induce EMT - such as transforming growth factor-beta 
(TGF-β), fibroblast growth factor (FGF), epidermal growth factor (EGF), and nuclear factor-
kB (NF-kB), and Wnt (Nieto et al., 2016). These pathways can activate one or more EMT-
driving transcription factors (EMT-TFs) such as SNAIL1, SNAIL2 (SLUG), TWIST1, ZEB1, 
ZEB2 (SIP1), PRRX1 and Goosecoid – each of which can directly or indirectly repress the 
cell-cell adhesion molecule E-cadherin (CDH1) – the hallmark of an epithelial phenotype (De 
Craene and Berx, 2013). On the other hand, signaling pathways such as retinoic acid (RA) 
(Biddle et al., 2016) that oppose TGF-β during lung development (Chen et al., 2007) can 
inhibit EMT.  
 
The well-established role of EMT in embryonic development and wound healing has driven 
investigations into its functional implications in carcinoma initiation and dissemination, and 
tissue fibrosis (Kalluri and Weinberg, 2009). Besides, EMT can contribute significantly to 
chemoresistance (Fischer et al., 2015; Zheng et al., 2015). We recently reported that hybrid 
E/M states, or equivalently, a partial EMT could be potentially more aggressive than a full 
EMT, and  (Jolly et al., 2015). EMT and MET are considered to be reversible, however, 
reversibility may depend on accompanying epigenetic modifications (Somarelli et al., 2016). 
 
In this review, we discuss the role of EMT in both lung development and lung diseases, 
highlight that EMT need not be a binary process in multiple contexts, and comment on EMT 
as a potential therapeutic target.  
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Lung histology and anatomy 
The respiratory system supplies oxygen to cells all over the human body and disposes them 
of carbon-dioxide, a respiratory waste product. Functionally a single unit, it connects the 
external environment with the internal extensively laid-out thin alveolar surface where gas 
exchange occurs. Thus, it coordinates breathing, transport of gases, gas exchange in alveoli, 
and also internal cellular respiration. This system is comprised of conducting airways that 
begins from the nose and ends at lung alveoli, following the path from nose to pharynx and 
larynx to  trachea, bronchi, and bronchioles, and finally the alveoli (Scanlon and Sanders, 
2007). 
The respiratory system constitutes upper respiratory tract (nasal air passages, nasal cavities, 
pharynx, larynx, and  trachea ) and lower respiratory tracts (trachea, branched lung bronchial 
tree (large airways), highly branched bronchioles (<2 mm in diameter, i.e. small airways), 
and finally the clusters of alveoli) (Kerr, 2010).  The mucosa of the upper respiratory tract 
consists of an outer ciliated epithelium lining, dense connective tissue lamina, a large smooth 
muscle bundle area, a continuous basement membrane, supporting cartilage structure, and 
intertwined goblet cells (mucus secretory cells). The cartilage, goblet cells, smooth muscles 
and the connective tissue gradually diminish as the respiratory system approach the tiny 
bronchioles, and are completely absent in the alveolus (Figure 2). Ciliated epithelial cells 
persist in the bronchioles, while goblet cells are replaced by non-ciliated dome shaped clara 
cells, present intermittently along the bronchiole epithelial lining. The clara cells carry out the 
important function of secreting surfactant proteins (Kerr, 2010). 
The connective tissue across the airway wall mucosal lamina have many resident interstitial 
cells, mainly comprised of fibroblasts. Fibroblasts produces extracellular matrix protein 
(ECM) such as fibers, collagen fibrils and varieties of proteoglycans, which are vital to 
maintain lung elasticity and their mechanical function (Burgess et al., 2016). Thus, there lies 
a distinct variability in structural and cellular composition across the lung that may have 
implications in various lung pathologies. For instance, thickening of reticular basement 
membrane – one of the two structural layers of the bronchial epithelial basement membrane – 
is usually observed in multiple pathological conditions such as chronic obstructive pulmonary 
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disease (COPD) and asthma (Figure 2), as discussed in detail later in this review. Also, in 
COPD, the basement membrane becomes fragmented as a result of EMT.  
EMT in lung development  
The first instance of EMT during embryonic development occurs during gastrulation when 
initially the mesenchyme is formed. Thereafter, multiple rounds of EMT and MET are often 
invoked in formation of various organs (Nieto et al., 2016). Particularly, during branching 
morphogenesis – a hallmark of organ development  such as lung, kidney and mammary 
gland, where a tubular epithelial structure splits repeatedly to generate a ductal tree, and the 
tip cells located at the front – also referred to as terminal end buds (TEBs) – display a partial 
EMT phenotype (Revenu and Gilmour, 2009). This process requires bidirectional 
communication between the epithelium and mesenchyme, mediated by multiple signaling 
pathways such as TGF-β /bone morphogenetic protein (BMP), Sonic hedhehog (Shh), 
retinoic acid (RA), FGF or Wnt (Bartis et al., 2014). During branching morphogenesis, TEB 
cells maintain cell-cell adhesion with their neighbours, and transiently acquire mesenchymal 
traits such as altered cell polarity and enhanced migration in response to extracellular signals. 
Consequently, these TEB cells state migrate collectively forming finger-like projections and 
are prevented from undergoing a full EMT by the action of ‘molecular brakes on EMT’ such 
as the transcription factors GRHL2 and its downstream target OVOL2 (Watanabe et al., 
2014; Aue et al., 2015; Walentin et al., 2015).  
 
GRHL2 is a transcription factor that exclusively mediates the development of both the 
airways and alveolar epithelium at all stages, but is absent in lung mesenchyme (Varma et al., 
2012). GRHL2-knockout phenotype is lethal at the beginning of lung development, 
underlining its key role in lung epithelium morphogenesis (Rifat et al., 2010). In lung 
epithelium, GRHL2 activates the transcription of a key lung transcription factor Nkx2-1, and 
that of E-cadherin (Cdh1) (Varma et al., 2012). Nkx2-1 can also reciprocally activate 
GRHL2, and both these transcription factors are among the top 25 activators of E-cadherin 
(Shimamura et al., 2011). Thus, this GRHL2/NKX2-1 feedback loop forms a central axis that 
contributes to preserving an epithelial phenotype (Varma et al., 2012). Besides, GRHL2 and 
its transcriptional target OVOL2 can regulate epithelium lumen formation via activating 
Rab25, Cldn4 (claudin 4) and Cldn3 (claudin 3) (Senga et al., 2012). Similar roles for 
GRHL2 have been mentioned in renal epithelium development (Aue et al., 2015). Such feed-
forward loop formed by GRHL2, OVOL2, and their targets typically stabilize the target gene 
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expression, thus emphasizing the role of GRHL2 in inducing and maintaining an epithelial 
identity (Mangan and Alon, 2003). Furthermore, GRHL2 is required for establishing human 
mucociliary airway epithelium (Gao et al., 2013). GRHL2 point mutations lead to many 
developmental defects such as reduction of lung size, and hindered lung inflation at birth, 
potentially due to reduced and/or mislocalized E-cadherin (Pyrgaki et al., 2011). In a nutshell, 
GRHL2 regulates a large repertoire of genes driving epithelial morphogenesis, intercellular 
adhesion, and cell motility in lung development, and may play similar roles in development 
of many other epithelial tissues (Werth et al., 2010). 
 
Besides its central role in orchestrating lung epithelium development, GRHL2 also regulates 
the expression of hTERT (human Telomerase Reverse Transcriptase) (Chen et al., 2010). 
Given that genetic mutations in hTERT may predispose for idiopathic pulmonary fibrosis 
(IPF) (Tsakiri et al., 2007; Alder et al., 2008), GRHL2 may be dysregulated in IPF 
progression. Consistent with its role in lung development, GRHL2 can (a) inhibit EMT-
inducing transcription factor ZEB1 directly, and is inhibited during TGFβ-mediated EMT 
(Cieply et al., 2012; Cieply et al., 2013; Xiang et al., 2017), (b) induce epithelial gene 
expression signature during cancer progression (Xiang et al., 2012), and (c) maintain 
collective migration in non-small-cell lung cancer (NSCLC) H1975 cells that display a stable 
hybrid E/M phenotype (Jolly et al., 2016). 
 
EMT in lung injury repair 
Lung homeostasis after injury depends on efficient recovery of an intact lung epithelium. In 
the airways, acute injury response on a timescale of 12-24 hours is cell spreading and 
migration, while proliferation of progenitor cells picks up later and may continue for weeks 
(Crosby and Waters, 2010). TGF-β, a potent EMT inducer, has been suggested to stimulate 
airway epithelial repair by inducing cell migration (Yu et al., 2008). These migratory cells 
that spread over large surfaces to provide an intact lining transiently gain mesenchymal 
features atleast partially (Vaughan and Chapman, 2013). Consistently, in a recent study of 
repair after napthalene-induced airway epithelium injury, SNAIL1 expression was induced, 
leading to a transient increase in Vimentin and αSΜΑ (alpha-smooth muscle actin) that 
contributes to regeneration of intact epithelial barriers (Volckaert et al., 2011). 
 
EMT in chronic lung disease 
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EMT is well described in lung embryogenesis (Lee et al., 2006), metastatic malignant disease 
(Bjornland et al., 1999), but it has only recently been recognised in the chronic human lung 
and airway diseases (Ward et al., 2005a; Willis et al., 2006; Hodge et al., 2009; Sohal et al., 
2010a; Sohal et al., 2011; Sohal and Walters, 2013b; Sohal and Walters, 2013a; Ojo et al., 
2014; Jonsdottir et al., 2015; Mahmood et al., 2015; Mahmood et al., 2017a). In the sections 
below, we will review the current literature on EMT in chronic lung disease.  
 
Chronic obstructive pulmonary disease (COPD)  
COPD is a diseased condition of inflamed lung and airways that leads to shortness of breath; 
this condition is progressive and irreversible, and mainly caused by smoking, (Sohal et al., 
2013b). however, other factors such as biomass fuel consumption has also been reported as 
major cause of COPD in countries like China and India (Kurmi et al., 2012). The prime 
pathology in COPD pertains to small airway fibrosis that leads to disrupted airway function 
(Sohal et al., 2013a). Small airway destruction occurs quite early in the disease and also often 
correlates with impaired lung tissue involved in gaseous exchange (a process called 
emphysema).  The other closely associated pathology with COPD is the development of 
airway epithelial cancer, predominantly in large airways (i.e. squamous cell carcinomas), 
although adenocarcinomas are also seen (Sohal, 2015). One potential mechanism which 
might be central to these pathologies is the process of EMT (Sohal et al., 2014a; Sohal, 
2015).  
 
EMT has been recently reported to be an active process in the airways of smokers and COPD 
patients. Several other groups have since confirmed these findings (Gohy et al., 2015; Milara 
et al., 2013). The reticular basement membrane (Rbm) in both small and large airways is 
often highly fragmented with many clefts (fissures or vertical indentations in the tissue) 
evident, which itself is a structural hallmark of active EMT (Sohal et al., 2010a; Soltani et al., 
2010; Sohal et al., 2011; Sohal and Walters, 2013a; Sohal and Walters, 2013b). Airway 
epithelium and cells within these clefts stained positive for markers of EMT and were found 
to be related to decrease in lung function and the smoking history. Co-expression of an 
epithelial marker cytokeratin and EMT marker S100A4 during COPD (Sohal et al., 2011) 
was indicative of cells undergoing partial EMT. A recent study furthered this notion and 
showed an increase in EMT-TFs and mesenchymal markers in human bronchial epithelial 
cells (HBEs) derived from COPD patients. Cultured media from  human COPD lung 
fibroblasts induced a partial EMT in HBEs, suggesting that interactions between resident 
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fibroblasts and epithelial cells may be critical in driving EMT in COPD (Nishioka et al., 
2015). 
 
To further contextualize EMT in smokers and COPD patients, we stained endobronchial 
biopsies and resected small airway tissue for vessel markers. We found large airway Rbm to 
be hyper-vascular whereas small airway to be hypo-vascular (Sohal and Walters, 2013d; 
Sohal and Walters, 2013c; Sohal et al., 2014a; Mahmood et al., 2015). Further, vessels were 
also observed penetrating into the epithelium in large airways. Active EMT associated with 
increased angiogenesis has been regarded as a hallmark of early growth of primary epithelial 
cancers (Kalluri and Weinberg, 2009). These observations fit well with the underlying 
pathology of COPD, i.e. cancer formation, especially squamous cell carcinoma, which is 
common in large airways (Sohal et al., 2014a; Sohal, 2015; Eapen et al., 2016).  
 
As mentioned earlier, we have also found active EMT in adenocarcinomas in smokers but the 
orgin of adenocarcinomas is debatable. Since small airway Rbm is devoid of active 
angeiogensis it is quite possible that adenocarcimomas might be orginating from type-II 
pneumocyte, but this warrants further work. We also recently reported transcriptional control 
of EMT in COPD, describing active Smad signalling in the airway. However, no significant 
correlation was observed for TGF-β1 expression and pSmad or EMT markers such as 
S100A4, suggesting that factors other than or in addition to TGF-β1 are also involved in 
modulating EMT during COPD (Mahmood et al., 2017a).   
 
Lung cancer and COPD share a common etiology i.e. tobacco smoking. Further, presence of 
COPD can increase the risk of developing of lung cancer by 4-5 folds, even when the 
smoking history is controlled for (Parimon et al., 2007a), implying that mechanisms specific 
to COPD may be involved in development of lung cancer (Petty, 2005; Kiri et al., 2009; Kiri, 
2010). Pathologically, COPD and lung cancer share many biological mechanisms, including 
chronic inflammation, ECM disruption, cell proliferation, abnormal wound repair and 
angiogenesis, and EMT (Yang et al., 2011; Sohal, 2017). EMT can play crucial roles in the 
pathogenesis of epithelial cancers (Tarin et al., 2005; Thompson et al., 2005); several key 
pathways driving EMT during embryogenesis get aberrantly activated in cancer. Very 
recently, we reported active EMT in the leading edge of invasive non-small cell lung cancer 
(NSCLC), both squamous cell and adenocarcinoma cell subtypes; the extent of EMT was 
strongly correlated with the aggressive behaviour of the tumor (Mahmood et al., 2017b). 
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Furthermore, EMT activity within the tumours closely correlated with EMT activity in non-
tumour–affected airway wall epithelium, suggesting that the level of EMT activity in the 
airway wall, even in large airways that are amenable to bronchoscopic biopsy, can potentially 
be used as a marker for smokers most likely to develop both COPD and lung cancer. These 
observations are clearly suggestive of EMT as a potential link between COPD and lung 
cancer (Sohal, 2015; Mahmood et al., 2017b; Sohal, 2017).   
The other prime pathology associated with COPD is small airway fibrosis and obliteration, 
and this could potentially be related to active Type-II EMT, as it does not involve 
angiogenesis usually (Mahmood et al., 2015). It is of interest and relevance in this context 
that over 90% of human cancer arises in epithelia, and the involvement of EMT in all of these 
may be central, specially in Type-III EMT that typically associates with angiogenesis 
(Garber, 2008; Barnes and Adcock, 2011; de Torres et al., 2011). COPD-related cancer may 
well be just another example of this core principle of unstable epithelium in the context of 
tissue inflammation and/or chronic stimulation (Nowrin et al., 2014; Eapen et al., 2016). Due 
to increased vascularity of the Rbm, it is also possible that the process of endothelial to 
mesenchymal transition (EndMT) – an analogous process to EMT – is also active in smokers 
and COPD (Sohal, 2016). EndMT has been reported to be crucial during fibrosis (Zeisberg et 
al., 2008), and similar to EMT (Jia et al., 2015; Jolly et al., 2015; Grigore et al., 2016; Nieto 
et al., 2016), EndMT need not be a binary process (Welch-Reardon et al., 2015), therefore 
fibrosis progression might involve multiple stages of EMT and EndMT.  
 
Lung cancer  
In cancer, induction of a partial or full EMT has been associated with enhanced tumor-
initiation potential (Mani et al., 2008; Morel et al., 2008; Jolly et al., 2014), resistance against 
multiple therapies (Singh and Settleman, 2010), immune-evasion (Tripathi et al., 2016), 
altered metabolism (Dong et al., 2013), and genomic instability (Comaills et al., 2016), thus 
suggesting implications of EMT in multiple hallmarks of cancer. EMT leading to single-cell 
dissemination has been long considered to be a key driver of the metastasis-invasion cascade. 
However, recent studies have questioned the indispensability of EMT in metastasis, but 
strengthened its proposed role of EMT in chemoresistance (Fischer et al., 2015; Zheng et al., 
2015). 
 
Particularly in NSCLC, EMT phenotype correlates with drug resistance, mutations of EGFR 
(epidermal growth factor receptor), and formation of Cancer Stem Cells (CSCs) characterized 
Page 9 of 31
John Wiley & Sons, Inc.
Developmental Dynamics
D
ev
el
op
m
en
ta
l D
yn
am
ic
s
by an enriched stem cell signature and a heightened tumorigenic potential (Bartis et al., 
2014). EMT can drive resistance to multi-targeted anti-folate (MTA) chemotherapy (Liang et 
al., 2015) as well as to EGFR inhibition (Thomson et al., 2005); NSCLC lines in a 
mesenchymal state were insensitive to growth arrest effect of EGFR inhibition both in vitro 
and in xenografts (Thomson et al., 2005). Further, the gefitinib-resistant subline of A549 – 
A549/GR – exhibited a spindle-shape morphology and higher levels of mesenchymal marker 
vimentin with concomitant decrease in CDH1, suggesting an EMT (Rho et al., 2009). Also, 
activation of TGF-β signaling in NSCLC cells can induce EMT and render cells insensitive to 
erlonitib; and erlotinib-resistant ‘mesenchymal-like’ cells are already present in cell lines and 
tumors prior to erlotinib treatment, indicating intratumoral heterogeneity (Yao et al., 2010). 
Finally, EMT can drive evasion against T-cell mediated immunotherapy; mesenchymal 
NSCLC cells display low levels of immunoproteasome and inhibit the production of relevant 
antigens for CD8+ T-cell presentation (Tripathi et al., 2016). Not surprisingly, 
immunoproteasome deficiency is associated with poor prognosis in NSCLC (Tripathi et al., 
2016). Thus, EMT lies at the nexus of resistance against multiple therapies. 
 
Also, induction of EMT via Dickkopf-1 (DKK-1) in NSCLC – a proposed biomarker for lung 
cancer (Yamabuki et al., 2007) – can drive vasculogenic mimicry (Yao et al., 2016) that may 
accelerate tumor aggressiveness by enabling direct access of blood vessels to cancer cells. 
Consistently, miR-206 that can inhibit HGF-induced EMT in NSCLC cells and reduce the 
migration and tube formation of human endothelial vascular cells (HUVECs) compromised 
metastasis and angiogenesis of lung cancer in vivo (Chen et al., 2016). Furthermore, TGF-β 
induced EMT in A549 cells can shift the metabolism towards more oxidative phosphorylation 
that can generate sufficient ATP needed for metastasis (Jiang et al., 2015). Therefore, EMT 
activation can modulate aggressiveness of NSCLC cells via multiple routes. 
 
Proteomic and morphological analysis of a panel of NSCLC cell lines reveal that similar to 
developmental EMT, EMT in lung cancer need not be an ‘all-or-none’ response; instead, 
many cells lines can display a hybrid E/M status (Schliekelman et al., 2015). These hybrid 
cell lines can contain both individual cells co-expressing epithelial and mesenchymal markers 
(H1975), and sub-populations of epithelial and mesenchymal cells (H2291) (Jolly et al., 
2016). Similarly, co-existence of subpopulations displaying epithelial, mesenchymal and 
hybrid E/M phenotypes was observed in multiple cell lines (i.e. isogenic populations) – 
A549, LT473, and H460 – in different ratios (Andriani et al., 2016), thereby indicating a role 
Page 10 of 31
John Wiley & Sons, Inc.
Developmental Dynamics
D
ev
el
op
m
en
ta
l D
yn
am
ic
s
of non-genetic heterogeneity in EMT decision-making (Lu et al., 2013; Mooney et al., 2016). 
Furthermore, in a cohort of 60 NSCLC patients, those displaying a balanced co-expression of 
CDH1 and SLUG (an EMT-TF) showed a significantly reduced survival, but neither of these 
markers alone was predictive of outcome (Andriani et al., 2016). These results strongly 
suggest the enhanced aggressive nature of a hybrid E/M phenotype as compared to the cells 
locked in a fully mesenchymal state. Consistently, the expression of GRHL2 – a ‘phenotypic 
stability factor’ that can maintain cells in a hybrid E/M phenotype – correlates with poor 
survival, independent of the breast cancer subtype (Mooney et al., 2017).  
 
A detailed comparison of multiple traits of hybrid E/M cells vs. fully mesenchymal cells still 
remains to be accomplished, but initial evidence in breast cancer indicates that cells co-
expressing an epithelial marker (CD24) and a mesenchymal marker (CD44), instead of those 
expressing a mesenchymal marker only, may manifest an adaptive drug-tolerant phenotype 
(Goldman et al., 2015; Boareto et al., 2016). These cells can possess enhanced tumor-
initiation potential both in vitro and in vivo as compared to canonically regarded CSCs in 
breast cancer – CD44+/CD24- (Goldman et al., 2015; Grosse-Wilde et al., 2015). Thus, 
further analysis of EMT in lung cancer both in the context of metastasis and drug resistance 
needs a careful and more nuanced classification regarding EMT status.  
 
Asthma  
Airway remodeling and thickening of basement membrane via collagen deposition has been 
consistently reported in asthma (Bergeron et al., 2010), but the exact source of this extra 
collagen deposition remains unclear. EMT has been proposed to be the source of fibroblasts 
that can deposit collagen and thus contribute to airway remodeling in asthma (Hackett, 2012).  
However, other major criteria for recognising EMT in vivo – Rbm fragmentation, 
accompanied by cell migration and expression of mesenchymal markers (Zeisberg and 
Neilson, 2009) – are typically not observed in asthma (Sohal et al., 2010b; Soltani et al., 
2012). In asthma, Rbm is thickened, but shows no sign of fragmentation, hypercellularity or 
hypervascularity. Hence, unlike in COPD, lung airways in adult asthma give no suggestion of 
an active EMT. However, published histopathology micrographs from asthmatic children are  
suggestive of  active EMT (Jenkins et al., 2003), and these neglected observations  deserve 
follow up.  
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Biochemical changes typically accompanying EMT can be induced in epithelial cell cultures, 
but such changes can be ‘metastable’, i.e. present only for a short period of time. Those 
changes do not necessarily reflect EMT rather a process called “reversible scatter”, where 
cells assume a spindle-like shape following cytokine stimulation, but the transcriptional 
changes are not sustainable; thus, upon withdrawal of the inducer, the epithelium returns to 
its original state (Kalluri and Neilson, 2003). Such response has been observed for alveolar 
epithelial cells (AECs) in culture upon TGF-β stimulation, but the asthmatic epithelium in 
vivo showed no empirical sign of EMT (Hackett et al., 2009). We believe that the current 
suggestions about EMT in the context of asthma are controversial and mainly based on 
molecular and cell culture techniques findings (Bartis et al., 2014), and the asthmatic tissue 
does not show the core structural hallmarks of EMT (Sohal et al., 2010b). 
 
Idiopathic pulmonary fibrosis (IPF)  
IPF is a devastating disease in which lung tissue becomes scarred (the condition of fibrosis) 
over time, thus obstructing the flow of oxygen from lungs into the bloodstream for 
distribution to other organs, and difficulty in breathing. With very limited treatment options 
and poorly understood underlying causes, IPF has a median survival of 3 years after 
diagnosis (Rudd et al., 2007). It is histopathologically characterized by heterogeneously 
distributed areas with progressive scarring in basal and lateral parts of the lung (King et al., 
2011). A hallmark for these scarred areas is the presence of distinct structures called 
fibroblast foci (FF) – collections of fibroblasts/myofibroblasts that produce ECM actively 
(King et al., 2011). Present at the boundary of normal and fibrotic tissue, these FFs denote the 
leading edge for the propagation of the tissue remodelling or scarring (Bagnato and Harari, 
2015). 
 
The source of myofibroblasts in FFs has been debated over the years, and they have been 
proposed to from resident tissue fibroblasts, bone marrow-derived progenitor cells (so-called 
fibrocytes), or from AECs that have undergone EMT (King et al., 2011). The proposition that 
AEC may be a source for fibroblasts/myofibroblasts in FFs has been supported by studies 
showing that AECs that circumscribe FFs express both mesenchymal and epithelial markers 
(Willis et al., 2005; Yamaguchi et al., 2016). Consistent with this notion, AECs isolated by 
laser microdissection from IPF patients expressed mesenchymal markers, such as collagen-1 
(Marmai et al., 2011). Furthermore, in vivo lineage tracing experiments in mouse models of 
pulmonary fibrosis have demonstrated that cells expressing mesenchymal markers had 
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epithelial origin, including AECs (Kim et al., 2006; Kim et al., 2009; Rock et al., 2011; 
DeMaio et al., 2012).  
 
However, the presence of these cells co-expressing epithelial and mesenchymal markers 
denotes an incomplete transition, and not necessarily a complete transition of an epithelial 
cell into a ECM-producing myofibroblast. Similar to these reports of incomplete transition, 
cells in alveolar epithelium of IPF lungs co-expressed epithelial marker GRHL2 with EMT 
markers VIM or ZEB1 (Varma et al., 2014), indicating a hybrid E/M phenotype. Similarly, 
bronchiolar basal metaplastic cells in IPF patients lose E-cadherin expression only partially 
(Morbini et al., 2011). Therefore, in most IPF studies, an EMT process was not observed to 
be fully completed. These observations concur with partial EMT observed in fibrosis of 
tubular epithelial cells of the mice. These cells do not completely convert to interstitial 
fibroblasts, but stay within the tubule and contribute to interstitial fibrosis, inflammation, and 
recruitment of immune cells (Lovisa et al., 2016). 
 
Several potential triggers can activate EMT in IPF. In 1980s, epithelial injury alone was 
shown to be able to trigger fibrogenic processes (Adamson et al., 1988). Many subsequent 
studies that have identified markers for epithelial injury and remodelling in IPF (Kuwano et 
al., 1996; Uhal et al., 1998) have commonly observed increased number of apoptotic/necrotic 
cells in alveolar epithelium, and stress markers – such as those for ER stress and for unfolded 
protein response (UPR) – in the surviving cells (Tanjore et al., 2012). AECs from a subset of 
individuals with familial pulmonary fibrosis (a scenario in which IPF occurs in many 
members of the same family) that are predisposed to develop the disease have been reported 
to be positive for ER stress and UPR markers (Mulugeta et al., 2005). These individuals also 
carry mutation in proteins that are exclusively expressed by alveolar type cells, such as 
surfactant protein C, surfactant protein A2 (Nogee et al., 2001; Wang et al., 2009), suggesting 
that ER stress caused by the mutations might contribute to disease development, by 
potentially inducing EMT in AECs, as shown in vitro (Tanjore et al., 2011; Zhong et al., 
2011).  
 
Besides ER stress, TGF-β1 is an important player in progression of fibrosis in many organs 
including the lung. TGF-β1 can induce both EMT with concomitant increase in α-SMA 
expression  and collagen-1 production in isolated AECs (Kalluri and Neilson, 2003), and has 
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the ability to differentiate fibroblasts into α-SMA-positive myofibroblasts that produce ECM 
in an exaggerated manner (Hu et al., 2003). Thus, overexpression of TGF-β1 may induce a 
prominent fibrotic response. Consistently, TGF-β1 blocking antibodies attenuate the fibrotic 
response in bleomycin-treated mice (Sime et al., 1997; Bonniaud et al., 2005). Increased 
staining of TGF-β1 has been reported in the alveolar epithelium in patients with IPF. Alveolar 
epithelium may both produced and activate TGF-β1 due to increased levels of integrin αvβ6 
(Munger et al., 1999) that can release and activate sequestered TGF-β1 in the ECM (Annes et 
al., 2003). Increased active TGF-β1 in the alveolar epithelium may stimulate repair responses 
such as EMT or differentiation of sub-epithelial fibroblasts. 
 
In summary, evidence for active EMT in IPF suggests it may play a role in the pathogenesis. 
To further understand the impact of EMT in IPF, it remains to be elucidated if EMT-derived 
cells can undergo a full transition into ECM-producing fibroblasts/ myofibroblasts in vivo.    
Bronchiolitis obliterans syndrome (BOS) 
Lung transplantation is an effective therapeutic option for carefully selected patients with 
advanced lung disease. Long-term survival after transplantation is, however, limited by 
chronic lung allograft dysfunction (CLAD) that prevents transplanted lung from functioning 
properly. CLAD most commonly manifests itself as Bronchiolotis Obliterans Syndrome 
(BOS) - defined by a sustained reduction in the forced expiratory volume in first second of 
expiration (FEV1). BOS may be observed in 50% of recipients within five years post-
transplant, and is associated with morbidity and mortality (Royer et al., 2016). Early 
identification of BOS, thus, represents a key goal for all transplant centres and new therapies 
are required.   
 
The pathophysiology of BOS involves inflammation, fibroblast proliferation and ECM 
deposition in the small airways. We have previously shown that BOS is accompanied by 
airway neutrophilia (an increase in neutrophilic lymphocytes) in both airway biopsies and via  
bronchoalveolar lavage (BAL) – a medical technique by which cells and fluid from the 
broncho-alveolar airspace  are isolated for disease diagnosis (Snell et al., 1997; Ward et al., 
1997; Zheng et al., 1997; Ward et al., 1998; Zheng et al., 2000; Whitford et al., 2001). 
Airway neutrophilia has been consistently reported in BOS by other transplant groups, 
despite the variation in patient management and sampling from the different centres (Royer et 
al., 2016). Neutrophils are a key producer of MMP-9, a type IV collagenase associated with 
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cell invasion and basement membrane damage. Thus, EMT may be exhibited in human 
airways in BOS (Ward et al., 2005b), as recently substantiated by an observed increase in 
three EMT markers - αSMA, S100A4, and EDA-FN (a splice variant of fibronectin) - by flow 
cytometry of brochial epithelial cells in BOS patients (Hodge et al., 2009). Intriguingly, these 
epithelial cells did not lose entirely the expression of epithelial cell antigen, thereby 
indicating a possibility of a hybrid E/M phenotype in BOS (Hodge et al., 2009). These 
observations are reminiscent of the first description of EMT in the human airway in a study 
of lung allograft patients that suggested EMT as an important process in BOS and 
pathophysiology of other common airway diseases (Ward et al., 2005a) , where 15% of cells 
in the airway epithelium in these biopsy samples co-stained for S100A4. 
 
Signalling pathways usually associated with EMT have also been observed to be active in 
BOS. We have shown that epithelial released alarmins (molecules released from damaged 
tissue to induce an immune response), TGF-β and SMAD signalling and infection can drive 
EMT in the lung allograft airway (Parker et al., 2008; Borthwick et al., 2009; Borthwick et 
al., 2010; Borthwick et al., 2011; Gardner et al., 2012; Suwara et al., 2014). Furthermore, we 
observed that members of miRNA200 family – a crucial brake on EMT (Park et al., 2008; 
Schliekelman et al., 2011; Lu et al., 2014; Huang et al., 2015; Sundararajan et al., 2015; 
Somarelli et al., 2016) – are  involved in a TGF-β driven EMT in BEAS2-B cells (normal 
primary epithelial cells) and primary airway cultures established from allograft brushings 
(Ladak et al., 2014; Ladak et al., 2016a; Ladak et al., 2016b). Consistent observations have 
been made by other groups. For instance, miR-21, a potential activator of EMT and CSC-like 
state (Han et al., 2012), was found to be overexpressed specifically in fibroblasts and in 
activated epithelial cells in all human BOS cases and in rat grafts, whereas it was absent in 
normal human and rat lungs (Di Carlo et al., 2016). Similarly, (a) miR-323a-3p that can 
attenuate TGF-β signaling by directly targeting SMAD2, was downregulated in epithelium of 
lungs with BOS after lung transplant (Ge et al., 2016); and (b) miR-144, a potential amplifier 
of TGF-β signaling, was overexpressed in lungs with BOS (Xu et al., 2015). With clinical 
trials showing promising results for miRNA leading to successful treatment of hepatitis, the 
abovementioned findings indicate that a greater understanding of the molecular 
pathophysiology of EMT may have therapeutic potential for both CLAD and BOS, and 
potentially other airway and lung diseases too.   
 
EMT as a therapeutic target 
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The current pharmaceuticals available to treat COPD does not really alter disease 
progression, at least when given late in the disease’s natural history as per the current 
convention. However, emerging evidence points that some of these drugs may affect the 
underlying process of EMT and therefore they may be more beneficial if given earlier. For 
example, Roflumilast™ (an inhibitor of phosphodiesterase-4 (PDE4) that elevates secondary 
signalling molecule cyclic adenosine monophosphate (cAMP)) has been shown to block 
cigarette smoke-induced EMT in bronchial epithelial cells (Milara et al., 2014). Inhaled 
corticosteroids (ICS) have been reported to protect COPD patients against lung cancer 
(Parimon et al., 2007) and we have reported that inhaling the corticosteroid fluticasone 
propionate suppresses EMT in COPD patients on six months treatment (Sohal et al., 2014b). 
This first study reporting anti-EMT effects of ICS in COPD demonstrated marked reduction 
in EGFR, Rbm fragmentation, S100A4 and MMP-9 expression in the active arm compared to 
placebo (Sohal et al., 2014b), but Rbm hyper-vascularity remained unchanged (Soltani et al., 
2016). It is quite possible that a longer treatment by ICS may also affect Rbm hyper-
vascularity. This anti-EMT effect of ICS may contribute, at least in part, to the effect that 
patients on ICS are associated with a significant (50%) reduction in the risk of lung cancer 
(Parimon et al., 2007b; Kiri et al., 2009; Kiri, 2010). 
 
Epigenetic inhibition of EMT has also been suggested, for instance, by sorafenib in A549 
lung adenocarcinoma cell line via an increase in histone acetyltransferase (HAT) expression 
and consequent decrease in histone deacetylase (HDAC) (Steiling et al., 2013). Similar 
effects of sorafenib are observed in liver (Chen et al., 2011) and urothelial carcinoma in situ 
(Steinestel et al., 2013) by targeting STAT3 and urokinase plasminogen activator (uPA). 
Targeted silencing of uPAR (uPA-receptor) using small hairpin RNA (shRNA) inhibited 
EMT in cultured human small airway epithelial cells (Wang et al., 2015). Camara et al 
suggested another potential therapeutic target for EMT - TGF-β1/Smad2/3 (Camara and Jarai, 
2010), which we found to be active and associated with EMT in smokers and COPD patients 
(Mahmood et al., 2017a). Yang et al. further demonstrated that crosstalk between muscarinic 
acetylcholine receptor (mAChR) and TGF-β1 can induce EMT in lung epithelial cells (A549) 
suggesting a role of non-neuronal cholinergic system in EMT and a potential novel 
therapeutic target for EMT (Yang et al., 2014). 
 
Similar to COPD, two drugs have recently been introduced in IPF which significantly 
decrease the rate of decline in lung function due to fibrosis (Brusselle and Bracke, 2014; 
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Richeldi et al., 2014). Nintedanib is a tyrosine-kinase inhibitor and pirfenidone mainly 
inhibits TGF-β1 agent. These drugs affect the key pathways implicated in EMT - Smad and 
β-catenin (Hostettler et al., 2014; Wollin et al., 2015; Cholankeril et al., 2016; Knuppel et al., 
2017). Nintedanib also inhibits angiogenesis, thus it may have implications for Type III EMT 
(pro-fibrosis and pro-cancer), while Pirfenidone is likely to be more specific to Type II EMT 
due to its anti-fibrotic action. 
 
Another putative anti-EMT agent is azithromycin (Banerjee et al., 2012), but part of its anti-
inflammatory properties can also be attributed to its action on macrophages (Banjanac et al., 
2012). Effects of azithromycin on epithelial cells seems to include modulation of 
transcription factors, ER stress, lysosomal accumulation, and excessive autophagy (Parnham 
et al., 2014). Similarly, other commonly used drugs for cardiovascular risk management that 
are not usually considered as respiratory treatment, but may yield long term fortuitous 
beneficial effects in COPD through mechanisms discussed earlier are statins (Yang et al., 
2013) and angiotensin-converting enzyme (ACE)-inhibitors (Qian et al., 2013). Indeed, 
atorvastatin can partially inhibit TGF-β1-driven EMT in small cell lung cancer cells (Fan et 
al., 2016), and ACE has also been implicated in EMT-driven metastasis in lung cancer (Qian 
et al., 2013).  
 
Conclusions  
We reviewed the implications of EMT in lung development, homeostasis, and many chronic 
lung diseases. From in vitro and in vivo studies in development, and pathological 
investigations of human samples, two key notions seem to emerge: a) functional role of EMT 
in driving the pathophysiology underlying COPD, BOS and IPF, and b) recognition of EMT 
not being a binary process with only two end-points. Very few studies have reported anti-
EMT effects of drugs. Data are especially sparse from in vivo human clinical investigations; 
most of the conclusions are drawn from in vitro studies. Thus, therapeutic approaches to 
block this profound epithelial plasticity are still in their infancy. Given the fact that disease-
associated EMT can be of two types – fibrosis and cancer, each with some unique phenotypic 
and signalling manifestations –  it becomes more complicated to tease out what 
proteins/pathways are contributing independently to fibrosis and cancer. Further in vivo 
studies and pathological investigations of human samples may have important translational 
insights regarding the progression of both these diseases, suggesting novel treatment 
strategies which are urgently required. 
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Figure legends 
Figure 1: EMT in lung development and disease. EMT and MET can be multi-step 
processes with potential intermediate or hybrid state(s) that can be stable phenotypes, i.e. may 
reflect the end of a transition unless otherwise perturbed (highlighted by STOP signs at a 
hybrid E/M phenotype). Key references implicating a partial or full EMT in lung 
development and other chronic lung diseases such as fibrosis, COPD, and lung cancer. 
Figure 2: Pictorial illustrations of the central compartment and their sub-divisions of 
human lung. Schematic adapted by permission from Macmillan Publishers Ltd. Nat Rev 
Cancer (Sun et al., ‘Lung cancer in never smokers: a different disease’), copyright (2007) 
shows the central compartment (top left), and structure of large bronchus (top right) and 
respiratory bronchioles (bottom left). Histological representation of thin-walled small airways 
(SA) (A and C) from normal non-smoker, thickened in COPD (B and D) (bottom right). A, B 
at 50X, and C, D. are at 200X magnification.  
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